Biovac signs deal with IVI to develop and manufacture oral cholera vaccine (OCV) for African and global markets.
List view / Grid view
Victoria Rees and Ria Kakkad from Drug Target Review bring you the key takeaways from the ELRIG Drug Discovery 2022 event in London.
Episode 13 – Multiplexing with Dr Luke Gammon, Queen Mary University & Dr David Pointu, Leica Microsystems
Join our experts as they discuss the advantages of multiplexed imaging for a wide range of research and how this technique will develop in the future.
Product hub: Light the path to your next neuroscience discovery with a new ultrasensitive NF-L immunoassay
Discover all the ways you can harness ultrasensitive immunoassays to stay at the forefront of neuroscience research.
The vaccine attaches spike proteins from SARS-CoV-2 and seven other SARS-like betacoronaviruses to a protein nanoparticle structure, to induce the production of a broad spectrum of cross-reactive antibodies.
New study has demonstrated that mice deficient in dendritic cell immunoreceptor are resilient against colitis and colonic tumour growth.
Scientists at the University of Pittsburgh have been using computational modelling to understand the body’s immune responses to avian flu.
Researchers in the US have developed a new CRISPR method for treating genetic conditions using nickases that they say is safer and more effective.
Researchers have created a new implant device has the potential to provide an alternative to opioids and other highly addictive drugs.
A new photonic effect in semiconducting helical particles with nanoscale dimensions has been discovered by an international team of scientists from the University of Bath, UK and the University of Michigan, US. Here, Professors Nicholas Kotov and Ventsislav Valev discuss their study and the observed effect which has the potential…
Expectations are growing worldwide for discoveries that will harness the potential of cell therapy, which has already brought breakthroughs in therapeutic areas where there is an unmet need, from oncology to ophthalmology and rare disease. In this article, Dr Terri Gaskell, Chief Technology Officer at Rinri Therapeutics, explores some of…
While the full potential of gene therapies continues to be realised, their successes in rare diseases promote them as a promising treatment modality. Dr Gaurav Shah, Chief Executive Officer of Rocket Pharmaceuticals discusses the future of gene therapies as well as the company’s progress in in vivo and ex vivo programmes.
In this article, Dr Mary Spellman, Chief Medical Officer and Senior Vice President of R&D at Castle Creek Biosciences, discusses how a versatile dual platform of ex vivo and in vivo gene therapy technologies is being utilised for the development of novel gene therapies for a broad range of rare…
Dr Richard Goodwin, Head of Imaging & AI, Clinical Pharmacology & Safety Sciences at AstraZeneca, explores the latest innovation in early therapeutic development – spatial biology.